Volume 3.08 | Feb 28

Hematopoiesis News 3.08, February 28, 2012
Hematopoiesis News
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
TOP STORY
Oncomir miR-125b Regulates Hematopoiesis by Targeting the Gene Lin28A
Investigating the mechanism by which microRNA-125b (miR-125b) regulates hematopoiesis, scientists found that, among a panel of candidate targets, the mRNA for Lin28A, an induced pluripotent stem cell gene, was most repressed by miR-125b in mouse hematopoietic stem and progenitor cells. [Proc Natl Acad Sci USA] Abstract

See Our Customized Services - In Vitro Assays To Assess Immunomodulation In Drug Development
PUBLICATIONS (Ranked by Impact Factor of the Journal)
LABORATORY RESEARCH

Unique Dual Targeting of Thymidylate Synthase and Topoisomerase1 by FdUMP[10] Results in High Efficacy Against AML and Low Toxicity
The novel fluoropyrimidine, FdUMP[10] was better tolerated than 5-fluorouracil (5-FU) or cytarabine plus doxorubicin and did not affect normal hematopoietic stem cells while 5-FU dramatically impaired their ability to engraft. In summary, FdUMP[10] was highly efficacious and better tolerated than standard therapies. [Blood] Abstract

CD86 Is Expressed on Murine Hematopoietic Stem Cells and Denotes Lymphopoietic Potential
Researchers show that CD86 CD150+ CD48 hematopoietic stem cells from normal adult mice are particularly poor at restoring the adaptive immune system. [Blood] Abstract

p38αMAPK Interacts with and Inhibits RARα: Suppression of the Kinase Enhances the Therapeutic Activity of Retinoids in Acute Myeloid Leukemia Cells
Here, scientists provide evidence that pharmacological inhibition of the mitogen-activated protein-kinase, p38α, or silencing of the corresponding gene sensitizes acute promyelocytic leukemia and acute myelogenous leukemia (AML) cell lines, as well as primary cultures of AML blasts to the anti-proliferative and cyto-differentiating activity of all-trans retinoic acid and synthetic retinoids. [Leukemia] Abstract

Selective FLT3 Inhibition of FLT3-ITD+ Acute Myeloid Leukemia Resulting in Secondary D835Y Mutation: A Model for Emerging Clinical Resistance Patterns
Researchers generated selective FLT3 inhibitor-resistant cells by treating the FLT3-ITD+ human acute myeloid leukemia cell line MOLM-13 in vitro with the FLT3-selective inhibitor MLN518, and validated the resistant phenotype in vivo and in vitro. [Leukemia] Abstract

Jdp2 Downregulates Trp53 Transcription to Promote Leukemogenesis in the Context of Trp53 Heterozygosity
Scientists performed a genetic screen in mice to identify candidate genes that are associated with leukemogenesis in the context of Trp53 heterozygosity. [Oncogene] Abstract

Estradiol Increases Hematopoietic Stem and Progenitor Cells Independent on its Actions on Bone
Investigators demonstrate that estradiol action on stromal cells potently favors hematopoietic progenitor/stem cell frequency accompanied by enhanced expression of cell adhesion molecules. [Haematologica] Abstract

Pontin Is Essential for Murine Hematopoietic Stem Cell Survival
Researchers find that Pontin is highly expressed in embryonic stem cells and hematopoietic tissues. [Haematologica] Abstract

miR-196b Directly Targets Both HOXA9/MEIS1 Oncogenes and FAS Tumor Suppressor in MLL-Rearranged Leukemia
Here investigators show that HOXA9 and MEIS1 are direct targets of microRNA (miRNA)-196b, a miRNA located adjacent to and co-expressed with HOXA9, in MLL-rearranged leukemic cells. [Nat Commun] Abstract

CLINICAL RESEARCH

Phase II Study of Rituximab Plus ABVD in Patients with Newly Diagnosed Classical Hodgkin Lymphoma
Investigators evaluated the efficacy and safety of rituximab in combination with standard doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients with classical Hodgkin lymphoma. [Blood] Abstract

Sorafenib Treatment of FLT3-ITD+ Acute Myeloid Leukemia: Favorable Initial Outcome and Mechanisms of Subsequent Non-Responsiveness Associated with a D835 Mutation
Thirteen relapsed or chemo-refractory fms-related tyrosine kinase-3- internal tandem duplication (FLT3-ITD+) acute myeloid leukemia  patients were treated with sorafenib (200-400 mg twice daily). [Blood] Abstract

Second Allogeneic Hematopoietic SCT for Relapsed ALL in Children
Scientists performed a retrospective analysis of 171 pediatric patients who received a second allo-SCT for relapsed ALL after allo-SCT. [Bone Marrow Transplant] Abstract

Free Wallchart: Identification Of Colonies Derived From Mouse Hematopoietic Progenitors
INDUSTRY NEWS
SymBio Announces Bendamustine Hydrochloride (SyB L-0501) Launch in Taiwan
SymBio Pharmaceuticals Limited announced that its licensing partner, InnoPharmax, Inc. has launched bendamustine HCl (SyB L-0501) under the trade name Innomustine® in Taiwan for the treatment of chronic lymphocytic leukemia and low-grade non-Hodgkin’s lymphoma as monotherapy in patients. [Symbio Pharmaceuticals Limited] Press Release

Virginia G. Piper Cancer Center Opens Cancer Transplant Institute
The Virginia G. Piper Cancer Center at Scottsdale Healthcare announced it has added a hematopoietic stem cell transplant cancer treatment program through its new Cancer Transplant Institute. [Scottsdale Healthcare] Press Release

ISSCR Honors Stem Cell Research Pioneer with Prestigious McEwen Award for Innovation
The International Society for Stem Cell Research (ISSCR) is pleased to announce the winner of the 2012 McEwen Award for Innovation, a coveted prize in the field of stem cell research and regenerative medicine. [International Society for Stem Cell Research] Press Release

ThinkCure! Awards $600,000 to Cancer Researchers at City of Hope and Children’s Hospital Los Angeles
ThinkCure! announced 12 new seed grants totaling $600,000 to cancer researchers at City of Hope and Children’s Hospital Los Angeles. The awards will fund the initial phase of cancer studies that offer promising insights into the development and growth of cancer cells as well as overall health outcomes for patients. [BusinessWire] Press Release
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
EVENTS
NEW The 2012 Stem Cell Discussion Forum
October 3, 2012
London, United Kingdom

Visit our events page to see a complete list of events in the hematopoietic community
JOB OPPORTUNITIES

Scientist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist (STEMCELL Technologies Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies Inc.)

Business Analyst – Product Management (STEMSOFT Software Inc.)

Postdoctoral Fellow in Cytokine Signaling in Hematopoietic Stem Cells (University of Pennsylvania School of Medicine)

Postdoctoral Fellow in Stem Cells and Cancer (Tsinghua University)

Postdoctoral/Research Associate (Children’s Memorial Research Center)

Pediatric Faculty – Hematology/Oncology Stem Cell Sciences (The University of Chicago)


Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe,
Middle East to Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us